Palvella Therapeutics Inc. Ordinary Shares PVLA 深 滬
等待開盤 09-18 09:30:00 美东时间
56.57
+2.060
+3.78%
華盛通- 最 高57.84
- 今 開54.78
- 成交量 23.89万股
- 最 低 54.48
- 昨 收 54.51
- 總市值 6.26亿
- 52周最高 61.4833
- 市盈率 靜 --
- 換手率 2.16%
- 52周最低 11.17
- 委 比 -26.32%
- 總股本 1105.97万
- 歷史最高 61.4833
- 量 比 2.06
- 振 幅 6.16%
- 歷史最低 11.17
- 每 手 1
- 風險率 12.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
Palvella Therapeutics announced the publication of a systematic review in *Lymphatic Research and Biology* outlining rapamycin's potential in treating cutaneous venous malformations (VMs). The review, analyzing 26 studies with 98 patients, highlights rapamycin's efficacy in VMs despite limited FDA-approved options. Palvella's QTORIN™ 3.9% rapamycin gel, currently in Phase 2 testing, targets the mTOR pathway linked to VM proliferation. Researchers...
09-17 11:30
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Palvella Therapeutics Accelerates U.S. Launch Planning
Palvella Therapeutics ( ($PVLA) ) has issued an announcement. On September 3, 2...
09-03 19:58
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
Palvella Therapeutics appoints David W. Osborne, Ph.D., as Chief Innovation Officer to advance its QTORIN™ platform, developing novel topical therapies for rare genetic skin diseases. With over 25 years of experience, Osborne will lead the expansion of the platform and a second QTORIN™ product candidate expected to be announced by year-end 2025.
09-03 11:30
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
Palvella Therapeutics' CEO, Wes Kaupinen, will speak at two healthcare investor conferences: the Cantor Global Healthcare Conference on September 4 at 2:45pm ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 10:30am ET. Both presentations will be webcast live and available for replay for 90 days on Palvella's website. Palvella focuses on developing novel therapies for rare genetic skin diseases without FDA-appr...
08-28 11:30
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $60
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $50 to $60.
08-15 19:25
Palvella Therapeutics Advances Rare Disease Pipeline
Palvella Therapeutics, Inc. ( ($PVLA) ) has released its Q2 earnings. Here is a...
08-15 12:59
Palvella Therapeutics Q2 EPS $(0.86) Misses $(0.73) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.73) by 18.46 percent.
08-14 19:31
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
Palvella Therapeutics, a clinical-stage biopharmaceutical company, announced it will report its second quarter 2025 financial results on August 14, 2025, and host an investor conference call at 8:30 a.m. ET the same day. The call will include a discussion of financial results and a corporate update. Investors can access the live webcast via the company’s website or the provided registration link. A replay will be available approximately two hours...
08-07 11:30
